Amesite Withdraws Public Offering Registration Statement

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: 6 days ago

0mins

AMST-3.67%

Should l Buy AMST?

Source: Newsfilter

Withdrawal of Registration Statement: On April 27, 2026, Amesite Inc. filed a request with the SEC to withdraw its S-1 registration statement originally submitted on April 20, 2026, indicating a significant strategic shift as the company no longer intends to pursue a public offering.
No Securities Sold: The registration statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering, highlighting potential challenges in the company's financing strategy that may impact future capital operations.
Core Product Advantage: Amesite's flagship product, NurseMagic™, reduces documentation time for nurses and caregivers from 20 minutes to just 20 seconds, enhancing operational efficiency and is utilized by over 100 professions across 50 states and 21 countries, showcasing its market potential.
Market Positioning and Compliance: Built on proprietary AI trained on industry-specific data, NurseMagic™ meets HIPAA regulations while improving accuracy and efficiency, indicating the company's strong competitive edge and compliance capabilities in the healthcare sector.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy AMST?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on AMST

About AMST

Amesite Inc. is a technology company. The Company focused on building and commercializing AI-powered solutions for the healthcare sector. The Company specializes in the development and marketing of business-to-consumer (B2C) and business-to-business (B2B) artificial intelligence (AI)-driven solutions, including its higher ed platform that offers professional learning. The Company's platform utilizes infrastructure to deliver both Amesite Engage for higher education and NurseMagic for healthcare. NurseMagic is a mobile app for healthcare professionals, streamlines creation of nursing notes and documentation tasks, enhances patient communication, and offers personalized guidance to nurses on patient care, medications, and handling challenging workplace situations. NurseMagic is designed for use across various healthcare modalities, such as skilled nursing, assisted living, memory care, home health, and rehabilitation centers.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Amesite Closes Private Placement of 696,866 Shares

5 days agoNewsfilter

Private Placement Completed: Amesite Inc. successfully closed a private placement of 696,866 shares of common stock at a price of $1.435 per share, expected to generate approximately $2.6 million in gross proceeds, thereby strengthening its capital base for future growth.
Warrants Issued: The placement included unregistered Series A-1 and A-2 warrants, each allowing the purchase of 696,866 shares at an exercise price of $1.435 per share, with potential additional gross proceeds of approximately $5.2 million if fully exercised.
Insider Participation: Company executives and board members participated in an insider-led private placement at a premium to market, involving 418,118 shares and corresponding warrants, reflecting management's confidence in the company's future prospects.
Compliance and Registration: The placement was conducted in accordance with Nasdaq rules and under a registered S-3 filing with the SEC, ensuring compliance and laying the groundwork for future capital operations.

Amesite Inc. Completes Sale of 696,866 Shares in Direct Offering

6 days agoNewsfilter

Stock Offering Details: Amesite Inc. announced the issuance of 696,866 shares of common stock at a price of $1.435 per share, with expected gross proceeds of approximately $2 million, reflecting the company's active engagement in capital markets and financing capabilities.
Warrant Issuance: The company will also issue unregistered Series A-1 and A-2 warrants to investors, each allowing the purchase of 696,866 shares at the same exercise price of $1.435, enhancing future financing flexibility.
Use of Proceeds: The net proceeds from this offering will be allocated for general corporate purposes, including working capital, indicating the company's strategic intent to expand operations and improve efficiency.
Market Reaction Expectations: Although there is uncertainty regarding the exercise of the warrants, if fully exercised, they could generate an additional approximately $4 million for the company, further supporting its innovative developments in the healthcare sector.